249 results about "Virulence" patented technology

The invention relates to the technical field of public health safety, and discloses a quantitative evaluation method and system for pathogen transmission risk, and the evaluation method comprises the following steps: step 1, obtaining virulence genes, reference virulence genes, environmental parameters, transmission factors and host risk factor parameters of pathogen samples; 2, performing variation detection on the virulence gene by adopting various variation detection algorithms to obtain all variation sites, and processing all variation sites to obtain effective variation sites; 3, constructing a virulence index model, inputting the variation distance into the virulence index model, and calculating the virulence index of the pathogenic bacteria sample; and 4, constructing a propagation risk assessment model, inputting the virulence index, the environmental factor, the propagation coefficient and the host susceptibility risk index into the propagation risk assessment model, and outputting a risk value by the propagation risk assessment model. According to the method, accurate prediction of the pathogen transmission risk can be realized.

The invention discloses a lytic bacteriophage vBVpaSR40Z and application of the lytic bacteriophage vBVpaSR40Z to prevention and control of vibrio parahaemolyticus in an aquaculture environment. The preservation number of the vibrio parahaemolyticus phage vBVpaSR40Z is as follows: GDMCC No: 67440-B1, and the vibrio parahaemolyticus phage vBVpaSR40Z is The R40Z can be used for cracking multiple strains of vibrio parahaemolyticus and vibrio alginolyticus, has the capability of adapting to an aquaculture environment, and keeps relatively high activity within the range of 4-25 DEG C and pH of 4-10; no virulence gene or drug-resistant gene is detected through genome analysis, and phylogenetic and whole genome comparison shows that the similarity between R40Z and a related phage is lower than a species level threshold value, so that R40Z is a new phage species; the R40Z can obviously inhibit the growth of a host under various infection complex numbers. The R40Z has the advantages of strong splitting capacity, good environmental stability, high genome safety, unique evolutionary characteristics and the like, and is an aquatic vibriosis biological prevention and control bacteriophage with application potential.

The invention provides a lactobacillus pentosus and a preparation method and application of bacteriocin of the lactobacillus pentosus. The name of the strain is lactobacillus pentosus YCL31, and the strain is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on June 25, 2025, the preservation address is the 5th floor of the building 59, No. 100 courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No: 66589. The bacteriocin separated and purified from the metabolite of the bacterium can destroy the morphological structure of the vibrio parahemolyticus and inhibit the toxicity of the vibrio parahemolyticus, can also achieve the effect of remarkably inactivating the vibrio parahemolyticus in a metapenaeus ensis system, can effectively delay the spoilage of the metapenaeus ensis, and has a good application prospect as a bacteriostatic agent or preservative. Therefore, development and application of the novel bacteriocin have important reference value in related fields.

A bacteriophage for specifically lysing high-virulence capsular Klebsiella pneumoniae, pertaining to the field of microorganisms. The deposit number of the Klebsiella pneumoniae bacteriophage vB_kpnP_D39 is CCTCC NO: M 2024690. In the bacteriophage liquid formulation prepared on the basis of the bacteriophage, the working titer of the bacteriophage is greater than 1 × 109 PFU / mL. The bacteriophage has high specificity and can kill all high-virulence multidrug-resistant Klebsiella pneumoniae of K1, K2, and K57 capsular serotypes, with an adsorption efficiency of 99.60%. The bacteriophage exhibits a biofilm clearance rate of 47.4%-63.2% and a capsule clearance rate of 42.1%-60.6% against the high-virulence Klebsiella pneumoniae. The bacteriophage is expected to become a safe, non-toxic agent for the prevention, control, and treatment of high-virulence multidrug-resistant Klebsiella pneumoniae infections, or an antibiotic adjuvant.

The invention discloses a verticillium dahliae virulence gene, a verticillium dahliae virulence protein and application. The invention relates to the technical field of biology, and provides a method for preventing and treating cotton verticillium wilt based on RNAi (RNA interference) as well as related components and application thereof. Specifically, the invention discloses application of the verticillium wilt prevention and treatment by a method for inhibiting or silencing the expression of verticillium dahliae pathogenic gene VdHDAC (coding protein of the verticillium dahliae pathogenic gene VdHDAC is shown as SEQ ID NO: 3), the core of the verticillium wihliae pathogenic gene VdHDAC is to provide dsRNA molecules capable of targeting the gene, and the positive-sense strand of the dsRNA molecules is preferably selected from SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 11. Based on the molecule, the invention further provides a recombinant vector containing the coding sequence, a recombinant microorganism, a transgenic disease-resistant plant and an RNAi pesticide preparation. The scheme can be realized through host-induced gene silencing, microorganism-mediated gene silencing or preparation treatment and the like, the virulence of pathogenic bacteria can be effectively reduced, and a new technical approach is provided for green prevention and control of verticillium wilt.

The invention belongs to the technical field of medicines, and provides a method for screening a mutant strain and a high-virulence Seneca virus A mutant strain. The method for promoting Senecavirus A mutation provided by the invention comprises the following steps: inserting an RNAi target sequence between 3Dpol and a 3'untranslated region of an SVA starting strain; the target sequence of the RNAi contains a complementary sequence of an endogenous sequence of the miRNA. According to the research, mutagenesis is carried out on SVA by constructing a high RNAi pressure system, and a method for screening the mutant strain SVA is carried out by simulating an antiviral RNAi mechanism in a host, so that a natural evolution process of the virus is better met, a large number of stably inherited mutant strains can be obtained, and an efficient research and development means is provided for vaccine research and development aiming at the virus.

The invention discloses a bacillus thuringiensis CMS-BT17, which is classified and named as bacillus thuringiensis, is preserved in the China General Microbiological Culture Collection Center (CGMCC), has the preservation number of CGMCC 35313, and is preserved on July 21, 2025. The bacillus thuringiensis strain CMS-BT17 directly separated and screened from a zizania aquatica soil sample in Haikou City of Hainan carries four insecticidal protein coding genes of Cry8Ca, Cry8Da, Spp1Aa and Vpb4Ca, not only is high in insecticidal toxicity and good in insecticidal effect, but also has a certain effect of inhibiting tomato fungal diseases, can be widely applied to prevention and control of agricultural diseases and pests, and has a wide application prospect. The sustainable development of green agricultural production is promoted.

The invention mainly provides Beauveria bassiana ZABb200102 and application of the Beauveria bassiana ZABb200102, the Beauveria bassiana ZABb200102 is preserved in China General Microbiological Culture Collection Center on October 28, 2024, and the preservation number of the Beauveria bassiana ZABb200102 is CGMCC (China General Microbiological Culture Collection Center) No. 41557. The strain is separated from sick lepidoptera cacalidae larva bodies for the first time, and it is found through toxicity determination that the strain has high pathogenicity to tomato leaf miner larvae. In addition, the strain can also be colonized in tomatoes, so that the growth of the tomatoes is promoted, and the resistance of the tomatoes to pests is indirectly improved. Therefore, the strain can be widely applied to development of tomato bacterial fertilizer and green prevention and control of tomato leaf miner which is an important tomato pest.

Novel strains of the insect-pathogenic fungus, Metarhizium var. anisopliae fungal strain BNL 101 deposited in the CABI UK Centre, United Kingdom, having IMI CC Number 506833; or BNL 102 deposited in the CABI UK Centre, United Kingdom, having IMI CC Number 506834; or a culture having the identifying characteristics thereof, are disclosed. The present invention also discloses methods of using the fungal strains, and spores obtained therefrom, to control insects, and provides a natural pest control preparation. The preparations and compositions comprise several unique and desirable features, such as a wide host range or alternatively a selective host range, and a consistent pathogenicity. The preparations and compositions have a high virulence (insecticidal activity), that is 2 times to 3 times, or greater, mor virulent (insecticidal) than compositions or preparations that do not contain the preparation or composition, and especially that do not contain the BNL 101 or BNL 102 fungal strain, or spores therefrom. The fungal strains also provide for a high spore yield in production, and possess a high stability in the field.

The application discloses a high-expression-based CRM197 protein specific neutralization detection method and belongs to the technical field of biological detection. The method comprises the following steps: S1, strain resuspension: Corynebacterium diphtheriae is resuspended to obtain a bacterial suspension; S2, bacterial liquid culture: the bacterial suspension is inoculated into an iron trichloride YC liquid culture medium to be cultured to obtain a bacterial liquid; and S3, specific neutralization: the bacterial liquid is inoculated on Elek's medium to be subjected to virulence determination. The application establishes a novel CRM197 protein specific neutralization detection method, greatly improves the technical requirements of detection effect and time limit, and provides a novel detection method for biological science.

The present disclosure belongs to the field of biotechnology, and specifically relates to a seven-component antigen African swine fever subunit vaccine. The present disclosure first provides an African swine fever virus antigen protein combination composed of the African swine fever virus P34 protein, P30 protein, P54 protein, A104R protein, C129R protein, X protein, and Y protein. This African swine fever virus antigen protein combination can induce a strong immune response in the host. Furthermore, the present disclosure provides a seven-component antigen African swine fever subunit vaccine including the aforementioned African swine fever virus antigen protein combination. The seven-component antigen African swine fever subunit vaccine exhibits good immunoprotection rates against challenge with the parental virulent African swine fever virus strain, poses no biosafety risks, overcomes the difficulty that existing African swine fever subunit vaccines domestically and internationally cannot provide effective immunoprotection for pigs.

This invention relates to the field of biomedical detection technology, providing a reagent, kit, and detection method for detecting *Vibrio cholerae* serogroup O139 using loop-mediated isothermal amplification (LAMP). This invention targets the synergistic regulation of the tcpA and hlyA genes in *Vibrio cholerae* serogroup O139, designing LAMP detection primers and establishing a LAMP detection method based on isothermal amplification. These LAMP detection primers or loop primers show promising applications not only against *Vibrio cholerae* serogroup O139 but also against other nosocomial infection bacteria. The LAMP primers for detecting *Vibrio cholerae* serogroup O139 can be used to detect *Vibrio cholerae* serogroup O139 in clinical patients or for outpatient screening. The kit of this invention can effectively and specifically detect single-reaction, single-copy, or higher copies of *Vibrio cholerae* serogroup O139. Compared to the "gold standard" real-time quantitative PCR, the kit of this invention offers higher accuracy and sensitivity, completing the detection within 30 minutes.

The invention discloses a vibrio canetinii bacteriophage capable of being split across species and application, the bacteriophage is a vibrio canetinii bacteriophage CP2 which is preserved in the China Center for Type Culture Collection with the preservation number of CCTCCM20251108, and the vibrio canetinii bacteriophage CP2 is preserved in the China Center for Type Culture Collection. The vibrio cantoniensis bacteriophage CP2 is a virulent bacteriophage separated from the nature, is free of genetic modification, has high safety and strong application potential, has an optimal infection complex number of 1: 10000, has a fermentation titer of 3.5 * 10 < pfu > / mL after 12 h, can rapidly split vibrio cantoniensis, has a recognition rate of 96.7% to 180 vibrio cantoniensis strains and a splitting rate of over 96%, and can be used for preparing the vibrio cantoniensis bacteriophage CP2. The genome does not contain toxicity and bad genes, the biological safety is high, the bacteriophage is excellent in environmental adaptability, stable in activity when the pH value is 6-8, high in storage stability at 4-25 DEG C, capable of being stored for 12 months at 4 DEG C, capable of stably surviving at room temperature, tolerant to a common chemical agent povidone-iodine for aquatic products, and suitable for various breeding scenes. Meanwhile, the cracking spectrum is wide, and the cross-species capability is realized.

The invention belongs to the technical field of biology, and particularly relates to a porcine pseudorabies virus gB-gD recombinant fusion protein subunit vaccine as well as a preparation method and application thereof. According to the invention, the PRV gB and gD genes are selected to serially express the gBgD protein to prepare the vaccine, the gB and gD proteins which are respectively expressed are replaced, and the vaccine is high in safety and good in immunogenicity, can effectively prevent the occurrence of a pseudorabies virus virulence enhancement event when being clinically used, provides a powerful space for purification of pseudorabies, and has a wide application prospect.

The present invention relates to engineered bacteriophages encoding and expressing at least one inhibitor of a quorum-sensing molecule. The bacteriophages of the present invention are useful for reducing, minimizing the virulence of, and / or eliminating pathogenic bacteria, such as those causing bacterial infections.

This invention discloses a nanoRNA delivery system and its application in the control of Sclerotinia sclerotinia disease, relating to the field of biotechnology. The preparation method of the nanoRNA delivery system includes the following steps: mixing chitosan, sucrose, and aspartic acid uniformly and then subjecting them to a hydrothermal reaction to obtain a quantum dot-chitosan degradation product complex; mixing the quantum dot-chitosan degradation product complex with double-stranded RNA to obtain the nanoRNA delivery system; the double-stranded RNA is used to silence Sclerotinia sclerotinia virulence-related transcription factor genes. The nanoRNA delivery system provided by this invention can effectively protect RNA and exhibits a very high inhibitory effect on Sclerotinia sclerotinia in plants, providing a novel technical solution for the green and precise control of Sclerotinia sclerotinia disease.

This invention discloses a broad-spectrum Staphylococcus aureus bacteriophage, SapYZUbeta, and its applications. This bacteriophage has been deposited at the China Center for Type Culture Collection (CCTCC) on May 16, 2022, with accession number CCTCC NO: M 2022629. Identification revealed that the full-length gene of this bacteriophage is 17,790 bp, and it does not contain tRNAs or genes associated with lysogenicity, virulence, or antibiotic resistance. This genetic background confirms the safety of this bacteriophage for use against foodborne pathogens and for bacteriophage therapy. Furthermore, the bacteriophage exhibits a high titer of 1.9 × 10⁻⁶. 9 The phage, with a concentration of PFU / mL, exhibits stable activity within a pH range of 3–12 and a temperature range of -80–60°C, and can be applied to various matrices. The phage provided by this invention can lyse multidrug-resistant wild-type strains isolated from different regions, including MRSA and MSSA, and is characterized by a broad lysis spectrum and high lysis efficiency.

The invention belongs to the technical field of microorganisms, and discloses a phage capable of efficiently splitting escherichia coli and salmonella, a preparation and application of the phage, the name is SP1, the classification name is escherichia coli phage, the preservation number is CGMCC No.46440, the preservation date is China General Microbiological Culture Collection Center on May 30, 2025, and the preservation unit is China General Microbiological Culture Collection Center. The optimal infection complex number of the bacteriophage is 1, the bacteriophage has very strong acid resistance and thermal stability, and the bacteriophage can keep high titer under the conditions that the pH value is 4-11, the temperature is 10-70 DEG C and the ultraviolet irradiation is within 30 minutes. The incubation period of escherichia coli infected by the bacteriophage is about 30 min, the outbreak period is about 40 min after the incubation period, and the bacteriophage can specifically split escherichia coli and salmonella, does not contain virulence and drug-resistant genes and is high in biological safety.

The application discloses a lytic bacteriophage vB_VpaS_R40Z and application thereof in preventing and controlling Vibrio parahaemolyticus in aquaculture environment. The Vibrio parahaemolyticus bacteriophage vB_VpaS_R40Z has a preservation number of GDMCC No: 67440-B1. The R40Z can lyse multiple strains of Vibrio parahaemolyticus and Vibrio alginolyticus, and has the ability to adapt to the aquaculture environment, and remains high activity within the range of 4-25 DEG C and pH 4-10; genome analysis does not detect virulence genes or drug resistance genes; phylogenetic comparison with the whole genome shows that the similarity of R40Z with the related bacteriophage is lower than the species level threshold, and R40Z is a new bacteriophage species; R40Z can significantly inhibit the growth of the host under multiple infection multiplicities. R40Z has the advantages of strong lytic ability, good environmental stability, high genome safety and unique evolutionary characteristics, and is a water product vibrio disease biological prevention and control bacteriophage with application potential.

The invention discloses a salmonella virulent bacteriophage vBSalPNW15 and application thereof, the bacteriophage is separated from farm sewage, belongs to a long-tail bacteriophage family, has a regular icosahedron head and a long-tail structure, and keeps stable under the conditions that the pH is 4-13 and the temperature is 40-60 DEG C. Genomic analysis shows that the kit does not contain virulence genes and drug-resistant genes and is good in safety. The bacteriophage and cinnamyl aldehyde are combined to be used for preventing and treating salmonella infection, both the bacteriophage and cinnamyl aldehyde show a remarkable synergistic bacteriostatic effect (FICI = 0.5) in vitro and in vivo, and the bacteriophage and cinnamyl aldehyde can effectively inhibit growth of multi-drug-resistant salmonella, remove biological membranes, relieve tissue pathological damage and remarkably improve the survival rate of chicks. The invention provides a safe and efficient antibiotic replacement scheme for preventing and treating salmonella infection, and is suitable for the fields of livestock and poultry breeding and food safety.

The present disclosure is directed to an approach using dsRNA to reduce or eliminate the production of DON by the fungal pathogen, F. graminearum or other fungal pathogens of the genus Fusarium and / or to control F. graminearum or other fungal pathogens of the genus Fusarium. In particular embodiments, methods and compositions are described to provide control of DON production and / or to control the fungal pathogen by causing mortality, suppression of growth, decrease in virulence or pathogenicity, or decrease in propagation / reproduction capacity (sporulation), by using exogenous dsRNA application administered to plants that are infected by or may become infected by F. graminearum or another member of the genus Fusarium that produces DON or otherwise is involved in Fusarium species complex that caused head blight.

The invention relates to the field of bioengineering, in particular to a recombinant human herpes simplex virus as well as a construction method and application thereof. The recombinant human herpes simplex virus lacks US1, US2, US3, US4 and US5 virulence genes at the same time. The construction method comprises the following steps: constructing a donor plasmid, and constructing a cleavage plasmid; transfecting cells with the cleavage plasmids and the donor plasmids in proportion; and after the transfected cells are incubated, infecting with an HSV-1 virus, purifying, and verifying to obtain the recombinant virus. The donor plasmid constructed by the invention retains non-coding regions among US1, US2, US3, US4 and US5 genes, also retains initiation codons and termination codons of the US1, US2, US3, US4 and US5 genes, is added with a fluorescent tag sequence, and can knock out five virulence genes of HSV-1US1-US2-US3-US4-US5 at the same time. The neutralizing antibody titer result of the recombinant human herpes simplex virus is the same as that of a wild type, and a foundation is laid for vaccine preparation.

This invention belongs to the field of microbial technology and discloses a strain of *Citrobacter freundii* bacteriophage PRF337, its bacteriophage composition, and its applications. The *Citrobacter freundii* bacteriophage PRF337 was deposited on May 26, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 46489. The bacteriophage PRF337 exhibits broad-spectrum bactericidal activity against *Citrobacter freundii*, capable of lysing *Citrobacter freundii* strains containing different virulence genes and from different sources. It also possesses certain temperature and pH stability and can be used as an active ingredient in pharmaceutical preparations, environmental disinfectants, and water purifiers. It can effectively control *Citrobacter freundii* infection in aquatic animals such as fish and shrimp in aquaculture environments and can also be used for the purification of pathogens in aquatic environments. It is safe to use and effectively avoids the problems of antibiotic residues and pathogen resistance caused by antibiotic use.

The application discloses application of an MgdE gene in regulating virulence of Mycobacterium bovis, a nucleotide sequence of the MgdE gene is shown as SEQ ID NO. 1, an amino acid sequence of a coded protein is shown as SEQ ID NO. 2, the protein coded by the gene is a nuclear regulatory protein, depends on two nuclear localization signal peptides (NLS) to play a nuclear localization function, and then inhibits a host inflammation level, enhances survival and colonization of the bacteria in a host cell, the two NLS are respectively located at positions 108-111 and 300-305 of the amino acid sequence shown as SEQ ID NO. 2. The MgdE gene or the two NLS is modified to obtain a weak strain of Mycobacterium bovis, it is found for the first time that the MgdE gene and the two NLS can be used as important targets for inhibiting Mycobacterium bovis infection. The application has important application value in preparation of Mycobacterium bovis bacillus Calmette-Guerin (BCG), and also makes an important contribution to exploration of a pathogenic mechanism and an immune escape strategy of Mycobacterium bovis.

The invention belongs to the field of biology, and particularly relates to construction of a recombinant Seneca virus strain with Seneca virus 2B protein translation block site mutation. The 26th lysine (K) of the 2B protein is found to be a key site for inhibiting the translation of the host protein for the first time, and after the 26th K of the 2B protein is mutated into the alanine (A), the translation retardation phenomenon of the host protein is obviously weakened; secondly, the 26th K of the 2B protein is mutated into A to construct infectious clone, and the recombinant Seneca virus strain rSVA-2B K26A with 2B protein translation retardation site mutation is successfully rescued and obtained, compared with wild type SVA, after the rSVA-2B K26A infects host cells, the translation retardation phenomenon of the host cells is weakened, the expression level of host antiviral inflammatory cytokines is enhanced, and the expression level of the recombinant Seneca virus strain rSVA-2B K26A is improved. The Seneca virus vaccine strain can be used as a potential vaccine candidate strain, and a foundation is laid for developing a novel prevention and control strategy aiming at the Seneca virus.

The invention discloses bacillus velezensis B116 and a preparation method of the bacillus velezensis B116. The bacillus velezensis B116 is prepared from bacillus velezensis, bacillus velezensis and bacillus velezensis. Belongs to the technical field of microbial technologies and animal probiotic preparations. The bacillus velezensis B116 obtained by screening has relatively strong biofilm forming ability, intestinal toxin-producing escherichia coli inhibiting activity, good self-aggregation and co-aggregation ability, excellent acid resistance, bile salt resistance, high temperature resistance and artificial gastrointestinal fluid characteristics, has no hemolysis and gelatinase activity, and does not carry drug-resistant genes and virulence genes. Animal experiments show that the strain has no acute toxicity to mice, does not influence visceral organ indexes, blood biochemical indexes and intestinal tissue structures, can significantly reduce the death rate of the mice after ETEC challenge and regulate the intestinal inflammatory factor level, has good probiotic effects and safety, and is suitable for development of feed additives or veterinary probiotics or veterinary drug products.

The invention discloses a PDCoV-S1 recombinant protein antigen as well as a preparation method and a vaccine thereof, and belongs to the technical field of recombinant protein vaccines. The amino acid sequence of the PDCoV-S1 recombinant protein antigen disclosed by the invention is as shown in SEQ ID NO: 1; the nucleotide sequence of the PDCoV-S1 recombinant protein antigen is as shown in SEQ ID NO: 2. The vaccine provided by the invention only contains recombinant PDCoV-S1 protein and does not contain genetic materials of viruses, so that all risks of virus replication, virulence reversion or gene recombination are fundamentally avoided. Live viruses do not need to be operated in the production process, so that the biological safety risk and the requirement on the production environment are greatly reduced. The constructed stable CHO engineering cell strain is combined with a serum-free suspension culture technology, so that high-density, large-scale and standardized production of the PDCoV-S1 protein can be realized in a bioreactor. The production process is stable and reliable, the batch-to-batch consistency is good, and the uncertainty and volatility caused by the virus culture link of the traditional vaccine are overcome.

The present application relates to a kind of targeting bacterial UDP-N-acetylglucosamine enolpyruvate transaminase antibacterial compound and its application, the antibacterial compound is S-(4-chlorobenzyl) chloro isothiourea, its chemical structure is as shown in formula I: I;Or its pharmaceutically acceptable salt, stereoisomer, solvate, crystal form, isotopically labeled or prodrug.The antibacterial compound of the present application can effectively inhibit the growth of klebsiella pneumoniae, including carbapenem-resistant klebsiella pneumoniae and high virulence klebsiella pneumoniae;It also has good bacteriostatic effect on escherichia coli and pseudomonas aeruginosa;It is expected to be applied to the clinical treatment of infection caused by drug-resistant klebsiella pneumoniae and high virulence klebsiella pneumoniae and other pathogenic bacteria, and has important clinical significance and social benefits.

This study describes the construction, identification, and application of a pseudorabies virus (PRV) triple-gene deletion vaccine strain (gI / gE / TK). Based on the JS-2012-ΔgI / gE double-gene deletion strain, the TK virulence gene was further deleted using CRISPR technology. Its pathogenicity was evaluated in KM mice and piglets, and its immunoprotective efficacy was verified in piglets. This provides theoretical support for the clinical prevention and control of pseudorabies; establishes experimental models in mice and pigs to study the immunoprotective efficacy of the triple-gene deletion strain; and prepares for the subsequent development and evaluation of vaccines using PRV strains as vectors.

The application discloses application of a carnation Italian ring spot virus P19 protein in regulating virulence of pseudomonas aeruginosa. The application finds that the protein can regulate synthesis of pyocyanin and affect virulence of the pseudomonas aeruginosa by constructing a recombinant expression vector of the carnation Italian ring spot virus P19 protein and transferring the protein into the pseudomonas aeruginosa, and the protein can be used for preventing and treating the pseudomonas aeruginosa, and a new method for preventing and treating the pseudomonas aeruginosa is provided.